Rostec to build unique oncology treatment center in Russian Far East
State Corporation Rostec and the administration of the Primorsky Krai, a federal subject in the Russian Far East, have signed an agreement to establish an oncology center of proton therapy in the Primorsky region. The health clinic shall admit its first patients in 2022, its annual capacity shall be over 1000 patients.
The health center which is unique for Russia shall be provided with advanced medical equipment allowing detection of diseases at early stages and precision sparing therapy. The agreement has been signed by Vasily Brovko, Director for Special Commissions of Rostec, and Andrey Tarasenko, acting governor of the Primorsky Krai, at the Eastern Economic Forum in Vladivostok.
Only few countries have comparable clinics: these include the USA, Japan and China. The center shall be established within the project for construction of similar clinics in the Russian regions, the aim of which is to improve availability of modern methods of diagnosis and cancer treatment.
The project shall be implemented in two stages. On the first stage Rostec shall provide a medical complex under construction in the territory of the Far Eastern Federal University (FEFU) with the following diagnostic equipment: PET and CT modular scanners and a modular cyclotron. This equipment shall allow detecting of neoplasms at early stages and timely prevent the disease progression. On the second stage, under the aegis of FEFU, a modern proton therapy center shall be built.
"Rostec is an active participant of the Healthcare National Project, one of the key directions of which is cancer control. Today, there is only one high-technology diagnostic and therapy center per every 2 million people in Russia. And there is only one PET/CT scanner allowing most accurate cancer detection per every 5 million Russians. The project we implement in cooperation with the regions and country's leading universities is aimed at the fundamental solution of these problems. Russian proton therapy centers shall be provided with the unique equipment," says Director for Special Commissions of Rostec Vasily Brovko.
Proton therapy is currently one of the most effective methods for cancer treatment which allows surgery to be avoided. The therapy requires special accelerator that produces a narrow beam of protons and by it locally impacts on a tumor without affecting neighbouring organs.
It is planned to establish the network of proton centers with such equipment in Moscow, Novosibirsk and Obninsk.
Rostec is a Russian state corporation that was established in 2007 to facilitate the development, production and export of high-tech industrial products designed for civilian and military applications. The Corporation comprises over 700 organizations that are currently part of eleven holding companies operating in the military-industrial complex and three holding companies working in civilian industry, as well as over 80 directly managed organizations. Rostec's portfolio includes well-known brands such as AVTOVAZ, KAMAZ, Concern Kalashnikov, Russian Helicopters, UralVagonZavod, etc. Rostec companies are located in 60 constituent entities of the Russian Federation and supply products to the markets of more than 100 countries. In 2017 the consolidated revenue of Rostec reached 1 trillion 589 billion rubles, while the consolidated net income and EBITDA amounted to 121 and 305 billion rubles respectively. In 2017 the average salary in the Corporation was 46,800 rubles. According to Rostec's strategy, the main objective of the Corporation is to ensure that Russia has a technological advantage in highly competitive global markets. Rostec's key objectives include the introduction of a new techno-economic paradigm and digitalization of Russian economy.
Rostec International Communications